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AbstrAct
Male breast cancer comprises less than 1% of breast cancer diagnoses. Although 
estrogen exposure has been causally linked to the development of female breast 
cancers, the etiology of male breast cancer is unclear. Here, we show via fluorescence 
in situ hybridization (FISH) and droplet digital PCR (ddPCR) that the Y chromosome 
was clonally lost at a frequency of ~16% (5/31) in two independent cohorts of male 
breast cancer patients. We also show somatic loss of the Y chromosome gene TMSB4Y 
in a male breast tumor, confirming prior reports of loss at this locus in male breast 
cancers.  To further understand the function of TMSB4Y, we created inducible cell lines 
of TMSB4Y in the female human breast epithelial cell line MCF-10A.  Expression of 
TMSB4Y resulted in aberrant cellular morphology and reduced cell proliferation, with 
a corresponding reduction in the fraction of metaphase cells.  We further show that 
TMSB4Y interacts directly with β-actin, the main component of the actin cytoskeleton 
and a cell cycle modulator. Taken together, our results suggest that clonal loss of the 
Y chromosome may contribute to male breast carcinogenesis, and that the TMSB4Y 
gene has tumor suppressor properties.
IntroductIon
Male breast cancer is a rare disease that is 100-fold 
less common than female breast cancer and accounts for 
less than 1% of all cancers in men [1, 2]. In the United 
States, approximately 210,000 women and 2000 men will 
be diagnosed annually with the disease [3, 4]. Globally, 
male breast cancer has an annual average incidence of <1 
case per 100,000 men [5]. Recent epidemiological studies 
show a slow but steady increase in the annual occurrence 
of this rare cancer [2, 6, 7]. 
Due to the low incidence of male breast cancer, most 
clinical and laboratory research has focused on female 
breast cancers [8]. However, studies from female breast 
cancers may not be entirely applicable to men since the 
etiology of male breast cancer remains unclear. Clinically, 
breast cancers are traditionally classified according to 
their receptor status, namely estrogen receptor (ER), 
progesterone receptor (PR), and HER2 (Human Epidermal 
Growth Factor Receptor 2). Similar to female breast 
cancer, the majority of male breast cancers are ER positive 
and/or PR positive [9]. A notable difference in male breast 
cancers compared to their female counterparts is the 
relatively lower percentage of ER, PR, HER2 negative 
(triple negative) and HER2 positive breast cancers 
[10-12]. Recent studies also highlight global genomic, 
transcriptomic, and proteomic differences between female 
and male breast cancers, with global gene expression 
profiling showing differences in at least 1,000 genes 
between female and male breast cancers [13]. In addition, 
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using a computer framework dubbed COpy Number and 
EXpression In Cancer (CONEXIC), cancer driver genes 
were shown to be distinct between male and female breast 
cancers [14].
Although it is unquestionable that exposure 
to estrogens is a major risk factor for breast cancer 
development in women, the fact that men can and do 
develop breast cancer, albeit at much lower incidence, 
speaks to the fact that other factors likely contribute to 
breast carcinogenesis. In this study, we hypothesized that 
the human Y chromosome may be involved in the etiology 
of male breast cancers. The Y chromosome is one of the 
smallest human chromosomes, and consists of a minute 
pseudoautosomal region (PAR) that is homologous to 
the X chromosome, and a larger male-specific Y region 
(MSY) [15]. Approximately 450 transcribed genes 
have been annotated on the Y chromosome, of which 
90 are protein-coding [16]. Early studies of male breast 
cancer genetics have provided some evidence that the Y 
chromosome may harbor a male specific tumor suppressor 
since partial or whole Y loss has been reported [17-19]. 
However, these reports involved small numbers of patients 
with low resolution genetic techniques. In addition, none 
of these studies examined Y chromosome in situ loss 
within tumor tissue, hindering the evaluation of clonal Y 
loss. To our knowledge, there are no reports evaluating in 
situ Y chromosome status in male breast cancers.
In this study, we addressed whether loss of the Y 
chromosome contributes to male breast carcinogenesis. 
Using fluorescent in situ hybridization (FISH) and 
droplet digital PCR (ddPCR), our results show clonal 
Y chromosome loss at a frequency of ~16% (5/31) in 
two independent cohorts of male breast cancer patients. 
Furthermore, we observed that Y chromosome loss can 
occur in ductal carcinoma in situ (DCIS) lesions. In 
order to identify a possible tumor suppressor within the 
Y chromosome, we used sequence-tagged-site PCR 
(STS-PCR) in male breast cancer specimens without 
Y chromosome loss, and show somatic deletion of the 
TMSB4Y gene in a male breast cancer patient, confirming 
prior reports showing loss of this region. We then created 
tetracycline-inducible clones of TMSB4Y in the human 
non-tumorigenic female breast epithelial cell line MCF-
10A. Our results show that induced expression of TMSB4Y 
led to aberrant morphological changes, persistent reduction 
in cell proliferation, and a corresponding reduction in the 
fraction of metaphase cells. Using proximity ligation 
assays (PLA) and immunoprecipitation with western 
blotting, we show that TMSB4Y interacts directly with 
β-actin, a main component of the actin cytoskeleton and 
a modulator of cell cycle progression. Taken together, 
our results show that in situ clonal loss of the human Y 
chromosome may play an important role in male breast 
cancer tumorigenesis, and suggest that TMSB4Y has tumor 
suppressive properties. 
results 
clonal loss of Y chromosome in male breast 
cancer is a frequent event
To address the hypothesis that Y chromosome loss 
may have a role in breast carcinogenesis, we first evaluated 
its loss in male breast cancers. We obtained FFPE tissue 
blocks of male breast cancers from 15 patients (cohort 1, 
Table 1) and used these to synthesize a tissue microarray 
(TMA). This TMA was then analyzed for Y chromosomal 
loss by FISH, along with an X chromosome FISH probe 
as a control (Figure 1). In order to survey the entire Y 
chromosome, we used various combinations of FISH 
probes specific for the short arm, centromere, and long 
arm of the Y chromosome (Figure S1). By these criteria, 
we observed clonal loss of the whole Y chromosome in 2 
out of 15 (~13.33%) male breast cancer patients. 
Next, we obtained 19 additional male breast cancer 
FFPE samples, however, only 17 had adequate tissue 
for analysis (cohort 2, Table 1). Because blocks were 
unavailable for these samples, we could not create a 
separate TMA. Therefore, we analyzed each specimen 
by FISH (Table 2), and demonstrated clonal somatic Y 
loss in 3 additional patients. Due to DNA degradation 
and limited material, 3 of 17 samples were inadequate for 
FISH yielding an overall Y loss frequency of 17% (5 of 29 
patients combining both cohorts). In order to analyze the 
remaining 3 samples that were unevaluable by FISH, we 
performed ddPCR on FFPE DNA using Taqman probes 
and primers specific to the X and Y chromosomes to assay 
for Y chromosome loss. As we have previously reported, 
fragmented DNA is optimal for ddPCR and minute 
amounts of DNA can be used for accurate quantification 
of alleles using FFPE derived material [20]. As seen in 
Table 2, the ratio of Y versus X positive signals (ratio 
Y/X) as measured by ddPCR was first validated using a 
commercial source of female and male control gDNA, 
with ratios of 0 and 0.966, respectively. We also included 
as a control a patient from cohort 1 with Y loss that showed 
a Y/X ratio of 0.193, supporting that ddPCR could be 
used to assess Y loss. As seen in Table 2, due to variability 
in tumor cellularity and non-tumor normal tissue 
contamination, tumors with Y loss generally had a Y/X 
ratio of less than 0.200, though the exception was patient 
5 who had a Y/X ratio of 0.410, likely due to a higher 
than observed amount of normal tissue contamination. 
Notably, we observed two cases, patients 3 and 4, with 
Y/X ratios of 0.354 and 0.383 suggestive of Y loss. 
However, for these two patients, FISH analysis showed Y 
retention with somatic duplication of the X chromosome, 
yielding an artificially lower Y/X ratio by ddPCR. These 
results highlight some of the potential pitfalls and caveats 
of allelic enumeration and ratios, and that in situ analysis 
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is often needed for definitive conclusions. Although one 
of the three patients with unevaluable samples for FISH 
yielded an equivocal result (patient 6), two patients clearly 
had Y/X ratios demonstrating retention of Y, though X loss 
could not be excluded in these patients (patients 14 and 
16). Thus, combining results from the two independent 
cohorts of male breast cancer patients using both FISH 
and ddPCR, we observed a Y loss frequency of ~17% (5 
of 29 male breast cancer patients), though if patients 14 
and 16 are included via the ddPCR results, the frequency 
is marginally decreased to ~16% (5 of 31 patients).
For one of the patient samples with Y loss in cohort 
1, a corresponding DCIS sample was available (Figure 
S2A), presenting an opportunity to ascertain whether 
Y loss occurred prior to invasive disease. As shown in 
Figure S2B, the DCIS from this patient was confirmed 
as non-invasive using an anti-smooth muscle actin stain. 
We further showed via FISH that this lesion had somatic 
Y loss, with the adjacent stromal tissue retaining the Y 
chromosome as an internal control (Figure S2C).
table 1: clinical characteristics of patients. The five Y loss cases are 
highlighted. nd, not done; na, not available.
cohort 1 
Patient er Pr Her2 stage
01 + + - IA
02 + + nd IA
03 + + nd IA
04 + + nd IA
05 + + - IA
06 + + nd IA
07 + Focally + Weakly + IIIC
08 + + nd IIA
09 + + nd IIA
10 + + Equivocal IIB
11 + - - IIIA
12 nd nd nd IA
13 + - - IIA
14 + - - IB
15 na na na na
cohort 2
Patient
01 + + na IIIB
02 + nd na 1
03 + + na na
04 + + na IIIB
05 nd nd na DCIS
06 nd nd na DCIS
07 + + + IIIB
08 + + na IIA
09 + + na IIA
10 + + na IA
11 + + na IIB
12 na na na IV
13 + + na IIA
14 + + na IA
15 + + na IIA
16 + - na IA
17 + - nd IV
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Figure 1: clonal loss of the Y chromosome in male breast cancer. FISH was performed to evaluate Y and X chromosomes on 
a male breast cancer tissue sample from a patient with clonal Y loss (top panels), normal breast tissue from the same patient as a somatic 
control (middle panels) and a male breast cancer sample without Y loss (bottom panels). Red, X chromosome FISH Probe; Green, Y 
chromosome FISH Probe; Blue, DAPI nuclear labeling. Original magnification: 20X.
Figure 2: TMSB4Y is lost in male breast cancer and expressed in normal male breast tissue. A. Regional Y loss was assessed 
by STS-PCR that was repeated 5 times using 5 serial slides from matched tumor and normal FFPE gDNA from three patients as described 
in the text. A summary of each STS-PCR is depicted as a decagon, where a positive reaction is red for tumor, and the corresponding normal 
somatic control is blue. b. Results summary for a patient who retained the Y chromosome in his breast cancer by FISH, but demonstrated 
consistent loss of the STS-PCR marker S17, a region containing the TMSB4Y gene, in tumor but not in adjacent normal tissue (outlined in 
green). Primer sets S13 and S27 were uninformative (shaded out) due to non-specific amplicons and lack of amplicons (amplicon size too 
large as described in text), respectively. c. Immunohistochemistry labeling for TMSB4Y was performed on normal breast tissue (left) and 
corresponding breast cancer (right) from a male breast cancer patient with known Y chromosome loss by FISH. Original magnification: 
20X.
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the Y chromosome gene TMSB4Y is lost in male 
breast cancer 
Although total Y loss was present in ~16% of 
our patient samples, we reasoned that if there was a 
tumor suppressor on the Y chromosome, deletion of this 
candidate tumor suppressor could occur with retention 
of the remainder of the Y chromosome. Microdeletions 
within the Y chromosome have been reported in males 
with varying degrees of frequency [21-23]. To further 
investigate this, we extracted gDNA from five male breast 
cancer patients who retained the Y chromosome, and 
amplified 33 Sequence Tagged Sites (STSs) within the 
MSY using standard PCR (Table S1, Figure S3). Primers 
were designed using published data for these genomic 
loci [24]. Paired tumor vs normal gDNA (identified by the 
study pathologist) were extracted from FFPE slides, but 2 
of 5 samples had inadequate gDNA for further analysis. 
The STS primer pair S27 was not successfully amplified 
in any tumor or normal samples, likely due to fact that this 
amplicon size is ~1kb, and could not be amplified from 
fragmented FFPE gDNA.
From the remaining 32 STS primer pairs, S17 did 
not amplify for the tumor gDNA for one of the three 
analyzable male breast cancer patients, but was present 
in the germline paired normal gDNA (Figure 2B). This 
primer pair amplifies a region including exon 1 and intron 
1 of TMSB4Y, a gene encoding the actin sequestering 
protein, Thymosin Beta 4, Y-linked. Prior literature also 
demonstrated that this region was lost in male breast 
patients with a frequency of 40% [25]. Furthermore, 
a query of the cBioPortal database using the parameter 
“TMSB4Y: HOMDEL” yielded a data set that shows 
TMSB4Y deletion in 16% (10/59) of metastatic prostate 
adenocarcinomas (Figure S4) [26]. To investigate whether 
TMSB4Y expression is consistent with a tumor suppressor, 
we sought to determine TMSB4Y expression in normal 













01 70 7 524 0.013 Y Loss Y Loss
02 60 6 114 0.053 Y Loss Y Loss
03 80 357 1009 0.354 Equivocal Y Retention *
04 80 217 566 0.383 Equivocal Y Retention *
05 60 84 205 0.410 Equivocal Y Loss
06 60 54 116 0.466 Equivocal Unevaluable
07 70 47 73 0.644 Y Retention Y Retention
08 70 17 24 0.708 Y Retention Y Retention
09 70 158 196 0.806 Y Retention Y Retention
10 80 57 52 1.096 Y Retention Y Retention
11 70 134 117 1.145 Y Retention Y Retention
12 70 334 214 1.561 Y Retention Y Retention
13 70 482 293 1.645 Y Retention Y Retention
14 60 156 91 1.714 Y Retention Unevaluable
15 80 2067 1188 1.740 Y Retention Y Retention
16 50 53 23 2.304 Y Retention Unevaluable
17 70 252 86 2.930 Y Retention Y Retention
Cohort 1 patient with 
Y loss 80 101 523 0.193 Y Loss Y Loss
Male gDNA NA 2628 2720 0.966 Y Retention Male Control
Female gDNA NA 0 3451 0.000 No Y Female Control
Tumor gDNA was extracted from FFPE tissue slides from male breast cancer patients and analyzed using ddPCR Taqman 
probes specific for X and Y chromosomes. Fourteen of 17 ddPCR-analyzable samples were validated by FISH; three patients 
had FFPE tissue that could not be validated with FISH.
* Denotes male breast cancer patients who have duplication of X chromosome.
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male breast tissue. We performed immunohistochemistry 
(IHC) to assess TMSB4Y protein expression in normal 
male breast tissue, using matched breast tumor tissue 
with Y loss as a negative control. Because TMSB4Y has 
a homolog located on the X chromosome, TMSB4X, 
we initially tested the specificity of the antibody. We 
transiently transfected TMSB4X and TMXB4Y cDNAs 
separately into HEK293 cells and harvested lysates 
for western blot. Unfortunately, none of our TMSB4X 
antibodies could detect TMSB4X protein, and therefore 
we obtained a FLAG-tagged TMSB4X cDNA and repeated 
the experiment. As shown in Figure S5, the TMSB4Y 
antibody specifically detected the TMSB4Y protein by 
western blot analysis but did not detect TMSB4X. 
We then performed IHC on our tissue sample. As 
shown in Figure 2C, normal breast epithelial cells labeled 
with strong intensity compared to the adjacent tumor 
tissue, which demonstrated no labeling above a low 
level of nonspecific background. These results show that 
TMSB4Y is expressed in normal male breast tissue and its 
expression is lost in a patient with known Y chromosome 
loss. Unfortunately, the TMA and tissue slides of MBC 
patients (both cohort 1 and 2) were exhausted and we 
could not perform IHC to evaluate TMSB4Y expression in 
our other MBC patients.
TMSB4Y expression alters breast epithelial cell 
morphology
To investigate the effects of TMSB4Y in breast 
cells, we generated stable Dox-inducible clones in the 
MCF-10A cell line [27]. MCF-10A is a genetically stable 
non-tumorigenic breast epithelial cell line derived from 
reduction mammoplasty tissue, and a derivative cell line, 
Figure 3: tMsb4Y expression in dox-inducible clones. The TMSB4Y cDNA was cloned into the pBI-EGFP vector and stably 
transfected into the Dox-inducible MCF-10A cell line, TetHyg2.5, to the create TMSB4Y Dox-inducible clones TmY1 and TmY2. HEK293 
cells were transiently transfected with empty vector (293 Empty Vector) or a TMSB4Y cDNA (293 TMSB4Y) to serve as negative and 
positive antibody controls, respectively. Parental TetHyg2.5, a stably transfected empty vector (EV) control cell line and the two inducible 
clones, TmY1 and TmY2, were placed in un-induced (-Dox) and induced (+Dox) media conditions for 48 hours prior to harvesting for 
lysates and fixation for FFPE blocks. TMSB4Y protein expression was verified via A.) western blotting using an anti-TMSB4Y antibody 
and GAPDH antibody as loading control, and b.) immunohistochemistry labeling of FFPE cell pellets using an anti-TMSB4Y antibody and 
counterstaining. Original magnification: 20X.
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TetHyg2.5, was created by stable transfection of the Tet 
repressor protein. MCF-10A cells are ideal for these 
studies, since they are non-cancerous, and therefore have 
less concern regarding pre-existing genetic alterations that 
could mask any given phenotype. In addition, they are 
derived from a female, so concerns regarding TMSB4Y 
expression are not applicable. TMSB4Y was cloned into 
the bidirectional pBI-EGFP vector, which contains the Tet 
response element, and expresses green fluorescent protein 
(GFP) simultaneously with TMSB4Y. We generated TmY1 
and TmY2, two Dox-inducible cell lines that express both 
GFP and TMSB4Y when induced with Dox. A control 
cell line was also created called EV, which contains the 
pBI-EGFP empty vector and expresses only GFP when 
induced with Dox. Expression of TMSB4Y after Dox-
induction was verified via western blotting (Figure 3A) 
and immunohistochemistry (IHC) on tissue cellblocks 
made from these cell lines (Figure 3B). We noted that 
TmY1 showed stronger induction of TMSB4Y compared 
to TmY2. 
After Dox-induction of TMSB4Y, we observed 
morphologic changes in TmY1 and TmY2 cells (Figure 
4), with cells displaying a flattened appearance with 
abnormal borders. Although EV control cells did not show 
morphology changes, we used as an additional control 
transient overexpression of GFP in MCF-10A cells and 
found this was non-toxic (Figure S6). Additionally, we 
performed immunofluorescence with antibodies against 
F-actin to better visualize the cellular architecture. As 
seen in Figure S7, F-actin labeling after Dox-induction 
confirmed aberrant cell morphology seen in TMSB4Y 
expressing cells. Because male breast cancers are most 
often ER positive, and MCF-10A are ER negative 
cells, we wanted to evaluate expression of TMSB4Y 
in an ER positive breast cancer cell line. As such, we 
then transiently co-expressed the TMSB4Y cDNA with 
GFP in the human breast epithelial adenocarcinoma 
cell line MCF-7. As seen in Figure S8, similar aberrant 
morphological changes were observed after 48hrs in GFP 
positive cells. 
tMsb4Y expression reduces cell proliferation
Tumor suppressors often reduce the proliferation of 
cells when expressed. In order to assess this phenotype, 
we compared proliferation rates of our cell lines with and 
without TMSB4Y expression. Dox-induction of TMSB4Y 
significantly reduced the growth rates of TmY1 and TmY2 
by approximately 30% when compared to TetHyg2.5 and 
EV (P < 0.05) in a 6-day growth assay (Figure 5A). This 
reduction in proliferation was persistent, as observed in 
a detailed growth assay where cell counts were taken on 
days 0, 3, 7, 13, and 18 (Figure 5B).
Figure 4: tMsb4Y expression leads to changes in cell morphology. Parental TetHyg2.5, a stably transfected empty vector (EV) 
control cell line and the two TMSB4Y Dox-inducible clones, TmY1 and TmY2, were placed in un-induced (-Dox) and induced (+Dox) 
media conditions for 48 hours and then imaged using phase contrast (Phase) and fluorescence (GFP) microscopy. Note the enlarged and 
aberrant cellular borders present in Dox-induced TMSB4Y clones, TmY1 and TmY2. Original magnification: 20X.
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To further understand the mechanism of reduced 
proliferation, we then performed fluorescence activated 
cell sorting (FACS) analysis on our cells. FACS was used 
to sort out the GFP-positive TmY1 cells 48hrs after Dox-
induction, and then these GFP-positive cells underwent 
cell cycle analysis based on their DNA content. TmY2 
cells could not be used for these experiments due to 
the low level of GFP inducible expression. TMSB4Y 
expression in these GFP-positive cells sharply reduced 
the metaphase fraction (G2/M) in TmY1 when compared 
to EV (Figure 5C). This metaphase reduction correlates 
with the persistent reduction in cell proliferation observed, 
suggesting that TMSB4Y expression modulates cell cycle 
progression.
TMSB4Y interacts with β-actin
Thymosin beta proteins have been identified as 
actin monomer sequestering proteins in mammalian 
cells [28, 29]. However, to our knowledge, there are no 
studies demonstrating that TMSB4Y directly interacts 
with actin. We reasoned that TMSB4Y might modulate 
cell cycle progression through a possible interaction 
with actin, a main component of the cytoskeleton [30]. 
In support of this, the intracellular actin cytoskeletal state 
has been shown to regulate cell cycle progression via 
retrograde signaling [31, 32]. To demonstrate a TMSB4Y 
interaction with actin, we performed a proximity ligation 
assay (PLA) using antibodies specific to TMSB4Y and 
β-actin. PLA employs two specific antibodies of interest, 
each containing a linked nucleic acid sequence such that 
proteins within 0 to 40nm of one another can then be 
ligated via their nucleic acid sequences, with subsequent 
amplification and fluorescence detection. Using PLA, 
we observed that TMSB4Y and β-actin are in close 
proximity in situ only after Dox-induction, supporting a 
direct protein-protein interaction (Figure 6A). We further 
confirmed this direct interaction between TMSB4Y and 
Figure 5: tMsb4Y expression reduces cell proliferation. Parental TetHyg2.5, a stably transfected empty vector (EV) control 
cell line and the two TMSB4Y Dox-inducible clones, TmY1 and TmY2, were placed in un-induced (-Dox) and induced (+Dox) media 
conditions and used for cell proliferation assays and FACS analysis. A. TmY1 and TmY2 exhibited ~30% of reduced proliferation upon 
Dox induction (*p < 0.05) relative to un-induced cells after 6 days of growth. b. Relative reduced cell proliferation after Dox-induction in 
both TmY1 and TmY2 was observed with prolonged culture as measured by cell counts at Days 3, 7, 13, and 18. c. TMSB4Y expression 
reduced the relative metaphase cell fraction in TMSB4Y expressing cells (TmY1) after Dox induction, but not in empty vector (EV) control 
cells after 48 hours and GFP-sorting for cell cycle analysis. 
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β-actin by immunoprecipitating β-actin with an anti-
TMSB4Y antibody in Dox-induced TmY1 lysates, 
however, this interaction was absent in Dox-induced EV 
lysates (Figure 6B). Together, these results suggest that 
TMSB4Y directly interacts with β-actin, and that this 
interaction may lead to the aberrant morphology and 
decreased proliferation seen upon TMSB4Y expression.
dIscussIon 
Cancer is a disease caused by a successive series 
of genetic alterations that lead to selective proliferative 
advantages in a single cell, which then expands into 
a tumorigenic clone [33]. Theoretically, all cells that 
originate from this clone will retain specific genetic “hits” 
acquired in this tumorigenic process. Therefore, our report 
of clonal in situ loss of the Y chromosome in ~16% of 
male breast cancers adds to the weight of evidence that Y 
loss contributes to male breast carcinogenesis. In accord 
with the clonal progression theory, we also observed 
clonal Y loss in a corresponding DCIS lesion from a male 
breast cancer patient, suggesting that Y loss can be an 
early event in male breast cancer, further supporting a role 
for early tumor formation.
We demonstrated that clonal Y loss was present in 
a percentage of male breast cancers via FISH. However, 
the capacity to perform FISH on FFPE tissues is variable 
due to the quality of DNA from this analyte. Therefore, 
we used ddPCR to determine Y loss in male breast cancer 
samples that were inadequate for FISH analysis. In 
theory, the loss of Y would skew the Y/X ratio towards 
zero. Previously, in an analysis of loss of heterozygosity 
of BRCA2 alleles, we showed that a basal level of 
contamination from surrounding normal stromal cells 
could be overcome using the highly sensitive and specific 
platform of ddPCR [20]. However, although normal 
cellular contamination is a common issue, X chromosomal 
duplication can also occur, as in 2 of our patients, making 
ddPCR less reliable to assess Y loss. However, our results 
do suggest that Y retention can be reliably concluded 
based upon the ratio of Y/X positive droplets using 
ddPCR. Thus, we included two of these patients in our 
overall assessment.
Figure 6: TMSB4Y interacts with β-actin. The empty vector control (EV) and TmY1 were grown in un-induced (-Dox) and induced 
(+Dox) conditions for 48 hours prior to assaying for TMSB4Y and β-actin protein interactions via A. a proximity ligation assay (PLA) 
using antibodies against TMSB4Y and β-actin as described in the text. The red signals (top right panel) demonstrate a TMSB4Y-β-actin 
interaction based on their in situ proximity of 0 to 40nm. Nuclei of cells are stained with DAPI (blue). Original magnification: 20X. b. Cell 
lysates were also used for immunoprecipitation (IP) experiments using a TMSB4Y antibody on Dox-induced lysates from EV and TmY1. 
The TMSB4Y antibody was used for IP, and then total lysate (1), supernatant after IP (2) or the IP fraction (3) was stained via western blot 
using anti-TMSB4Y and anti-β-actin antibodies.
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Our results showing Y loss support recent studies 
suggesting that the human Y chromosome has tumor 
suppressive functions. For example, mosaic loss of Y 
chromosome in peripheral blood is associated with a 
higher risk of non-hematologic cancers in men [34]. 
Furthermore, this loss of Y in peripheral blood is 
associated with smoking in a dose-dependent manner 
[35], suggesting a possible link with smoking and Y 
loss. Additionally, male microchimerism in women 
has been shown to reduce the risk of breast cancer by 
approximately one third [36]. In fact, male chimerism 
observed in the peripheral blood of women generally 
increases the survival of women affected by cancers and 
cardiovascular diseases [37]. Male microchimerism is a 
phenomenon that occurs in pregnant women with male 
fetuses, with subsequent exchange of fetal and maternal 
cells via the placenta and persistence of fetal cells [38]. 
In addition, a previous study demonstrated that transfer 
of the Y chromosome into a prostate cancer cell line with 
Y loss suppressed formation of xenografts in 59 out of 
60 athymic nude mice [39]. Collectively, these previously 
described reports combined with our data strongly suggest 
that the human Y chromosome harbors tumor suppressive 
properties.
Upon observing Y loss in 5 out of 31 (~16%) of our 
male breast cancer patients, we hypothesized that male 
breast cancer without Y loss may still have deletion of a 
candidate tumor suppressor gene. Therefore, we utilized 
STS-PCR to investigate regional Y loss in male breast 
cancer patients with Y chromosome retention. Using STS-
PCR, we showed somatic loss of an STS containing the 
TMSB4Y gene in one of three of our male breast cancer 
patients with Y retention (Figure 2A). A previous study 
using array comparative genomic hybridization (aCGH) 
demonstrated a 40% (10/25 patients) deletion of the 
Yq11.1-q11.221 locus in male breast cancer, a region that 
contains TMSB4Y [25]. Furthermore, an analysis of public 
databases via cBioPortal showed that TMSB4Y was deleted 
in 16% (10/59) prostate cancer samples (Figure S4) [40]. 
These combined data further support that TMSB4Y is a 
tumor suppressor whose loss contributes to male breast 
cancer. 
Functional analysis of TMSB4Y also suggests 
this gene has tumor suppressor properties. When 
TMSB4Y is overexpressed in a Dox-inducible MCF-10A 
background, we observed altered cell morphology, 
reduced cell proliferation, and a reduced G2/M population. 
Mechanistically using PLA and immunoprecipitation, we 
showed that TMSB4Y directly interacts with β-actin. Since 
β-actin is a main component of the actin cytoskeleton, a 
major factor in cell morphology and a regulator of cell 
cycle progression [31, 32], the direct interaction of 
TMSB4Y and β-actin may modulate the actin cytoskeletal 
turnover in cells, and in turn could alter cell morphology 
with subsequent retardation of cell cycle progression. 
In conclusion, we observed that ~16% of male 
breast cancers demonstrate in situ clonal loss of the Y 
chromosome. These data and those of others, support 
our hypothesis that the human Y chromosome may be a 
tumor suppressor in male breast cancer. Furthermore, the 
Y chromosome gene TMSB4Y may be a tumor suppressor 
gene that normally functions through its direct interaction 
with β-actin, which in turn regulates cell morphology and 
cell proliferation. These results lend new insights into the 
potential role of the Y chromosome as a tumor suppressor 
and implicate TMSB4Y in the etiology of male breast 
cancers.
MAterIAls And MetHods 
Formalin fixed paraffin embedded (FFPE) tissue 
of male breast cancer patients
Thirty-two male breast cancer samples were 
collected from 2 independent cohorts. Cohort 1 consists 
of 15 male breast cancer patients from Johns Hopkins 
Hospital collected from 1990 to 2013. FFPE tissue blocks 
were available and samples were used to create a tissue 
microarray (TMA) for analysis under an IRB approved 
protocol. Cohort 2 consists of samples from 19 male 
breast cancer patients from the Veterans Affairs Medical 
Center, Washington DC collected between 1996 to 2012. 
The study was approved by the IRB, VAMC DC. We were 
able to extract genomic DNA from 17 of these 19 FFPE 
samples that was suitable for droplet digital PCR (ddPCR), 
though only 14 had suitable quality and quantity for both 
ddPCR and fluorescence in situ hybridization (FISH). 
FIsH
FFPE tissue slides were de-paraffinized and washed 
with xylene and EtOH. Slides were pretreated, hybridized 
with FISH probes, and then mounted for microscope 
observation. Pretreatment was performed using 
Pretreatment Kit I (02J02-032, Abbott Molecular). Probes 
were mixed with LSI/WCP Hybridization Buffer (06J67-
001, Abbott Molecular). Slides were counterstained with 
DAPI, and mounted with ProLong® Gold (P36930, 
Invitrogen). All fluorescence microscopy photos were 
imaged with NIS-Elements BR2.30. All FISH probes used 
were from Abbott Molecular: Vysis CEP X (DXZ1) SO 
Probe (centromeric, 05J08-033), Vysis CEP X (DXZ1) 
SA Probe (centromeric, 05J09-033), Vysis CEP Y (DYZ1) 
SGn Probe (q arm, 05J10-034), Vysis CEP Y (DYZ3) SO 
Probe (centromeric, 05J08-035), and Vysis LSI SRY SO 
Probe (p arm, 05J27-089).
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droplet digital Pcr (ddPcr)
As previously described, ddPCR was performed 
using the QX100™ Droplet Digital PCR System 
according to the manufacturer’s recommendations 
(Bio-Rad) [41]. TaqMan® Copy Number Assays (Life 
Technologies) included Hs00314226_cn (FAM labeled) 
and Hs04125506_cn (VIC labeled) probes. Control 
genomic DNA used for these studies were commercially 
purchased male (Promega, G1471) and female (Promega, 
G1521) DNA. ddPCR was performed with Bio-Rad’s 
recommended two-step thermo-cycling protocol with 
a 58°C annealing/extension step. All data analysis was 
performed using QuantaSoft (Bio-Rad).
Genomic dnA (gdnA) extraction from FFPe 
tissue slides
Tumor and normal areas were identified and 
marked by the study pathologist (P.A.). Tissue slides 
were de-paraffinized and pinpoint solution (D3001-1, 
Zymo Research) was applied specifically onto the marked 
areas. DNA was then extracted using the QIAmp DNA 
FFPE tissue kit (56404, Qiagen) as per the manufacturer’s 
protocol.
sts-Pcr
The male specific region of the Y chromosome 
Breakpoint mapper [24] was used to analyze the sequence-
tagged sites (STS) status of gDNA extracted from patients. 
Thirty-three sets of STS primers across the MSY region 
(Table S1) were used. Each set of STS-PCR was repeated 
5 times for reproducibility.
cell culture
TetHyg2.5, a derivative of the non-tumorigenic 
human breast epithelial cell line MCF-10A [27] was 
grown in DMEM/F12 (1:1) supplemented with insulin 
at 10 µg/mL, hydrocortisone at 0.5 µg/mL, and cholera 
toxin at 0.1 µg/mL (hereafter denoted as “supplemented 
DMEM/F12”), 5% horse serum (Gibco), EGF at 20 ng/
mL, and hygromycin B at 14.3 µg/mL. Dox-inducible 
TetHyg2.5 derivatives (EV, TmY1, TmY2, and UA3) were 
grown in supplemented DMEM/F12 with 5% Tetracycline 
(Tet)-free FBS (HyClone), EGF at 20 ng/mL, hygromycin 
B at 7.15 µg/mL, and G418 at 120 µg/mL. HEK293 and 
MCF-7 cells were grown in DMEM media with 5% FBS. 
All supplements were purchased from Sigma-Aldrich 
unless otherwise specified. MCF-10A, HEK293, and 
MCF-7 cells were purchased from American Type Culture 
Collection (ATCC).
Plasmids and transfections
The TMSB4Y cDNA was purchased as pCMV6-
XL5-TMSB4Y (Origene) and was subcloned into the 
pBI-EGFP vector (Clontech). The TMSB4X cDNA 
was purchased as tagged and untagged plasmids as 
pCMV6-Entry-TMSB4X and pCMV6-XL5-TMSB4X, 
respectively (Origene) and used for transient transfection 
experiments in HEK293 cells. Plasmids were amplified 
using the Qiagen Hi-Speed Maxi kits (Qiagen) as per 
the manufacturer’s protocol. Transient transfections 
were carried with FUGENE6 (Promega) as per the 
manufacturer’s protocol. 
Generation of dox-inducible clones
TetHyg2.5 cells were seeded on day 0 and 
transfected with a cDNA of TMSB4Y cloned into the pBI-
EGFP vector and a neomycin resistance vector on day 1. 
Selection media (hygromycin B at 7.15 µg/mL, and G418 
at 120 µg/mL) was used from day 2 onwards. On day 5, 
cells were plated into 96-well plates and observed for 
clones expressing green fluorescent protein (GFP) upon 
48-hr doxycycline (Dox)-induction at 2ug/ml. Two clones, 
TmY1 and TmY2, were identified as Dox-inducible 
cell lines, and an empty vector control (EV) was also 
generated.
Immunoblotting
Whole-cell protein lysates were prepared using 
Laemmli sample buffer and resolved by SDS-PAGE 
using NuPAGE gels (Invitrogen), transferred to a 0.2 µm 
pore size Invitrolon polyvinylidene difluoride (PVDF) 
membranes (Invitrogen), and probed with primary 
antibody followed by incubation with horseradish 
peroxidase-conjugated secondary antibodies. Antibodies 
used include anti-TMSB4Y (clone 6G4) mouse monoclonal 
antibody (SAB1403013, Sigma Aldrich), anti-FLAG 
M2 antibody (200472-21; Agilent), anti-rabbit IgG 
HRP-linked antibody (7074, Cell Signaling Technology), 
anti-mouse IgG HRP-linked antibody (7076, Cell 
Signaling Technology), anti-GAPDH (D16H11) XP rabbit 
monoclonal antibody (5174, Cell Signaling Technology), 
and anti-β-actin (clone 13E5) rabbit monoclonal antibody 
(4970, Cell Signaling Technology).
cell line tissue block
Cells were trypsinized and fixed in 10% buffered 
formalin overnight. Cells were then centrifuged and 
resuspended with 1X PBS, then mixed via pipetting with 
2% agarose solution. Agar plugs were processed into 
FFPE tissue blocks and slides.
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Immunohistochemistry (IHc)
IHC was performed using the PowerVision + Poly-
HRP anti-Mouse IHC Detection System (Immunovision). 
Briefly, slides were steamed in EDTA solution and 
incubated with anti-smooth muscle actin antibody mouse 
monoclonal (1:800 dilution, DAKO, m0851) or anti-
TMSB4Y (clone 6G4) mouse monoclonal antibody (1:200 
dilution, SAB1403013; Sigma Aldrich). Poly-HRP anti-
mouse IgG antibody was applied and then visualized 
with 3,3’-diaminobenzidine (Sigma). Slides were 
counterstained with hematoxylin.
cell proliferation assay
Cells were seeded in supplemented DMEM/F12 
with 1% Tet-free FBS (HyClone), EGF at a physiological 
concentration (0.2 ng/mL), hygromycin B at 7.15 µg/mL, 
and G418 at 120 µg/mL. Dox induction was performed 
by seeding cells in their respective media with 2µg/mL of 
Dox. 2 x 104 cells per well of a 6-well tissue culture dish 
were seeded on day 0. Media was changed every third day, 
and cells were harvested for cell counting on days 3, 6, 7, 
13, and 18 using a Beckman Coulter® Vi-CELL™ XR 
Cell Viability Analyzer. 
Proximity ligation assay (PlA)
Cells were seeded in chamber slides and Dox for 
induction x 48 hours. Slides were fixed in cold methanol 
for 15min in -20°C and treated with cold acetone for 1 
minute at room temperature. Mouse monoclonal anti-
TMSB4Y antibody (Clone 6G4, SAB1403013, Sigma 
Aldrich) at 1:200 and rabbit monoclonal anti-β-actin 
antibody (Clone 13E5, 4970, Cell Signaling Technology) 
at 1:200 were incubated overnight. PLA was performed as 
per instructions of the DuoLink® In Situ Red Starter Kit 
Mouse/Rabbit (DUO92101, Sigma Aldrich).
Immunoprecipitation
Cells were rinsed with ice-cold PBS, scraped, and 
lysed on ice in lysis buffer containing 1% Triton X-100, 
10% glycerol, 100mM NaCl, 50mM Hepes (pH 7.2), 
10mM NaF (all from Sigma Aldrich), 10mM Na3VO4 
(New England Biosciences), and minitab cOmpleteTM 
protease inhibitor with EDTA (Roche). Lysates were 
quantified using the BCA protein assay reagent (Pierce). 
Immunoprecipitation was performed by incubating 1mg 
of lysate with 1µg of anti-TMSB4Y antibody (Clone 6G4, 
SAB1403013, Sigma Aldrich) overnight at 4ºC. Lysates 
were then incubated with Dynabeads Protein G (Life 
Technologies) for 4 hours at 4ºC. Dynabeads were then 
washed with cold lysis buffer and boiled at 100 ºC for 5 
minutes in 2x Laemmli buffer before immunoblotting.
Cell-cycle analysis with flow cytometry
Cells were seeded at 50% confluency in T75 flasks 
and Dox-induced for 48hrs. GFP positive cells were 
isolated by fluorescence activated cell sorting using BD 
FACSAria II and fixed in PBS/3% formaldehyde/0.4% 
NP-40 containing 2 mg/mL Hoechst 33258 (Invitrogen). 
DNA content was measured with a BD LSR flow 
cytometer (BD Biosciences), and percentages of G1/G0, 
S, and G2/M phase cells were determined using Modfit LT 
software (Verity Software House).
statistical analysis
All statistical analyses were conducted with 
GraphPad Prism software. For the t-tests conducted, 
p<0.05 was considered significant.
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